Impact of genetic polymorphisms on clinical response to antithrombotics.

about

Clinical application of high throughput molecular screening techniques for pharmacogenomics.Genetic Discoveries in Atrial Fibrillation and Implications for Clinical Practice.

P2860

Q36441517-9C88B306-02B5-4B2D-8F32-B0EEDC96363D Q38719268-CF929F50-D534-436A-A2EA-958438F7E751

P2860

Impact of genetic polymorphisms on clinical response to antithrombotics.

Item

http://www.wikidata.org/entity/Q36441477

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Impact of genetic polymorphisms on clinical response to antithrombotics.

@ast

Impact of genetic polymorphisms on clinical response to antithrombotics.

@en

type

Item

label

Impact of genetic polymorphisms on clinical response to antithrombotics.

@ast

Impact of genetic polymorphisms on clinical response to antithrombotics.

@en

prefLabel

Impact of genetic polymorphisms on clinical response to antithrombotics.

@ast

Impact of genetic polymorphisms on clinical response to antithrombotics.

@en

P1476

Impact of genetic polymorphisms on clinical response to antithrombotics.

@en

P2093

Julie H Oestreich

http://www.w3.org/2001/XMLSchema#string

Kena J Lanham

http://www.w3.org/2001/XMLSchema#string

Steven P Dunn

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients

Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

P304

87-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/PGPM.S9597

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Steven R Steinhubl

P577

2010-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23226045

http://www.w3.org/2001/XMLSchema#string

P932

3513211

http://www.w3.org/2001/XMLSchema#string

Impact of genetic polymorphisms on clinical response to antithrombotics.

about

P2860

P2860

Impact of genetic polymorphisms on clinical response to antithrombotics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932